Literature DB >> 21135556

Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias.

Mirko Bibl1, Brit Mollenhauer, Piotr Lewczuk, Hermann Esselmann, Stefanie Wolf, Markus Otto, Johannes Kornhuber, Eckart Rüther, Jens Wiltfang.   

Abstract

BACKGROUND/AIMS: We determined cerebrospinal fluid (CSF) concentrations of amyloid-β (Aβ)(1-38), Aβ(1-40), Aβ(1-42), total tau and phospho-tau (p-tau) in order to study their differential expression in frontotemporal dementia (FTD, n = 25) and primary progressive aphasia (PPA, n = 12) as compared to Alzheimer's dementia (AD, n = 25) and nondemented controls (n = 20).
METHODS: Commercially available ELISA and electrochemiluminescence methods were applied.
RESULTS: High CSF p-tau and low ratios of Aβ(1-42)/Aβ(1-40) and Aβ(1-42)/Aβ(1-38), respectively, were specific for AD. CSF Aβ(1-38) was reduced in FTD as compared to each of the other diagnostic groups, including PPA. CSF tau and p-tau levels were elevated in PPA as compared to FTD.
CONCLUSION: This is the first detailed report on biomarker patterns in PPA, indicating distinct CSF biomarker patterns in FTD and PPA as major subgroups of frontotemporal lobar degeneration. The diagnostic and pathophysiological implications of our results warrant further studies on larger and neuropathologically diagnosed patient populations.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21135556     DOI: 10.1159/000322370

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  14 in total

Review 1.  Clinical phenotypes and genetic biomarkers of FTLD.

Authors:  Daniela Galimberti; Elio Scarpini
Journal:  J Neural Transm (Vienna)       Date:  2012-04-19       Impact factor: 3.575

2.  Association of Cerebrovascular and Alzheimer Disease Biomarkers With Cholinergic White Matter Degeneration in Cognitively Unimpaired Individuals.

Authors:  Nira Cedres; Daniel Ferreira; Milan Nemy; Alejandra Machado; Joana B Pereira; Sara Shams; Lars-Olof Wahlund; Anna Zettergren; Olga Stepankova; Lenka Vyslouzilova; Maria Eriksdotter; Stefan Teipel; Michel J Grothe; Kaj Blennow; Henrik Zetterberg; Michael Schöll; Silke Kern; Ingmar Skoog; Eric Westman
Journal:  Neurology       Date:  2022-08-02       Impact factor: 11.800

3.  Supporting evidence for using biomarkers in the diagnosis of MCI due to AD.

Authors:  Samantha Galluzzi; Cristina Geroldi; Giovanni Amicucci; Luisella Bocchio-Chiavetto; Matteo Bonetti; Cristian Bonvicini; Maria Cotelli; Roberta Ghidoni; Barbara Paghera; Orazio Zanetti; Giovanni B Frisoni
Journal:  J Neurol       Date:  2012-10-16       Impact factor: 4.849

4.  Neurochemical biomarkers in Alzheimer's disease and related disorders.

Authors:  Mirko Bibl; Hermann Esselmann; Jens Wiltfang
Journal:  Ther Adv Neurol Disord       Date:  2012-11       Impact factor: 6.570

5.  Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia.

Authors:  Mirko Bibl; Marion Gallus; Volker Welge; Hermann Esselmann; Stefanie Wolf; Eckart Rüther; Jens Wiltfang
Journal:  J Neural Transm (Vienna)       Date:  2012-04-19       Impact factor: 3.575

Review 6.  Frontotemporal lobar degeneration: current perspectives.

Authors:  Lina Riedl; Ian R Mackenzie; Hans Förstl; Alexander Kurz; Janine Diehl-Schmid
Journal:  Neuropsychiatr Dis Treat       Date:  2014-02-13       Impact factor: 2.570

7.  Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians.

Authors:  Pedro Rosa-Neto; Ging-Yuek Hsiung; Mario Masellis
Journal:  Alzheimers Res Ther       Date:  2013-11-25       Impact factor: 6.982

Review 8.  Clinical significance of fluid biomarkers in Alzheimer's Disease.

Authors:  Piotr Lewczuk; Marta Łukaszewicz-Zając; Piotr Mroczko; Johannes Kornhuber
Journal:  Pharmacol Rep       Date:  2020-05-08       Impact factor: 3.024

9.  Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease.

Authors:  David J Irwin; John Q Trojanowski; Murray Grossman
Journal:  Front Aging Neurosci       Date:  2013-02-21       Impact factor: 5.750

Review 10.  Truncated and modified amyloid-beta species.

Authors:  Markus P Kummer; Michael T Heneka
Journal:  Alzheimers Res Ther       Date:  2014-05-26       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.